Christopher Hite
Showing 1–2 of 2 transcripts.
- Milken Institute57 min
Turning Back Time: The Science of Aging
Joanne Kenen, Nir Barzilai, Howard Fillit, Christopher Hite, Joan Mannick, Joanne Cannon, Sami, Aditi Ramdurai, San, Sarah Locke
A panel of experts led by Nir Barzilai, Christopher Healy, Howard Federoff, and Joan Manik is advocating for a paradigm shift in geroscience from treating individual chronic conditions to targeting the underlying biology of aging. The group is pursuing "healthspan compression" through concrete initiatives like the TAME metformin trial, TORC1 inhibitor development, and combination therapies designed to delay multiple diseases simultaneously. While regulatory hurdles and ethical concerns regarding long-term drug use remain, these efforts aim to prove that extending healthy life is economically viable and socially transformative.
- Milken Institute1h 1m
World-class Healthcare: Investing in Biomedical Innovation
Tanisha Carino, Christopher Hite, Bryan Johnson, Sean Parker, D.A. Wallach
Moderated by Dr. Tanisha Carino in Abu Dhabi, this session analyzed the convergence of global biomedical innovation and market dynamics, highlighted by the historic $92 billion Bristol-Myers Squibb acquisition of Celgene as a catalyst for pipeline stability. The discussion detailed how falling hard science costs and platforms like Ginkgo Bioworks are compressing development timelines, while investment strategies increasingly favor foundational tools over singular disease treatments to address the translational gap between academic research and commercial viability. Despite concerns regarding venture capital concentration in oncology and systemic US healthcare incentives, the event projected that long-term pricing decreases and extended lifespans could emerge from global regulatory evolution and the integration of AI-driven data collection.